Biopharmaceutical Innovation and Value
This article was originally published in RPM Report
Executive Summary
Bristol-Myers Squibb’s top US commercial executive reflects on the impact pharmaceutical innovation has had on patients, the importance of separating “true” innovators from bad actors in the pricing debate – and on the urgency to do even more to help patients as quickly as possible.